MA07.07 Validation Analysis of MET IHC as a Biomarker for Amivantamab-Lazertinib Response in Post-Osimertinib EGFR-Mutated NSCLCBenjamin Besse, E. Felip, L. Paz-Ares et al.|Journal of Thoracic Oncology|2025Cited by 1